Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144468 · ClinicalTrials.gov registry record
Effects of Exemestane on Bone Strength
A clinical trial, sponsored by University Health Network, Toronto.
- Completed
- Registry status
- 351
- Enrollment target
NCT01144468 is a clinical trial that has completed, run by University Health Network, Toronto. The registered enrollment target is 351 participants.
The verdict
NCT01144468 has completed, sponsored by University Health Network, Toronto.
- COMPLETED
- Registry status
- 351 participants
- Enrollment target
Study Summary
The NCIC CTG was conducting an international breast cancer prevention trial (MAP.3) examining the effects of a new therapy (exemestane) for breast cancer prevention in postmenopausal women at increased risk of developing this disease. Results showed that after a median follow up of 35 months, exemestane was superior to placebo in breast cancer prevention. Exemestane blocks estrogen production, which may be beneficial for preventing breast cancer, but may have negative effects on bone. As postmenopausal women are at risk for developing osteoporosis, determining whether exemestane causes bones to weaken is crucial for women considering it for long-term use. Dr. Cheung's team followed the bone health of 354 women in MAP.3 in detail over 2 years and found that volumetric bone mineral density (by high resolution peripheral quantitative computer tomography (HR-pQCT) at the radius and tibia as well as areal bone mineral density by dual energy x-ray absorptiometry (DXA) at the hip and spine decreased significantly with the use of exemestane. The long term effects of exemestane on bone will be examined up to 5 years of therapy and then 2 years post therapy to delineate the effects of exemestane on bone strength. This research will inform us on the safety of exemestane for breast cancer prevention.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2007-04 |
| Est. Completion | 2022-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01144468
The ClinicalTrials.gov registry entry for NCT01144468 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Health Network, Toronto, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01144468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01144468 about?
NCT01144468 is a clinical study titled "Effects of Exemestane on Bone Strength". The NCIC CTG was conducting an international breast cancer prevention trial (MAP.3) examining the effects of a new therapy (exemestane) for breast cancer prevention in postmenopausal women at increased risk of developing this disease. Results showed that after a median follow up of 35 months, exemes...
What is the current status of trial NCT01144468?
This trial is currently completed. The enrollment target is 351 participants. The study started on 2007-04. Estimated completion is 2022-01.
Who is sponsoring clinical trial NCT01144468?
This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.